PMID- 18441768
OWN - NLM
STAT- MEDLINE
DCOM- 20080703
LR  - 20181201
IS  - 0011-4162 (Print)
IS  - 0011-4162 (Linking)
VI  - 81
IP  - 2
DP  - 2008 Feb
TI  - Terbinafine-induced subacute cutaneous lupus erythematosus.
PG  - 156-7
AB  - Terbinafine is a synthetic oral allylamine that is used for systemic treatment of 
      microscopy- or culture-proven dermatophyte infections of skin and nails. It is 
      normally well-tolerated and side effects include transient gastrointestinal 
      symptoms and skin reactions that can occur in up to 2.3% of treated patients. 
      Subacute cutaneous lupus erythematosus (SCLE) is a skin reaction that has been 
      reported secondary to use of a variety of drugs. The number of reports of SCLE 
      with terbinafine is limited. We demonstrate 2 patients in one dermatology clinic 
      who presented with a predisposing autoimmune diathesis within 3 months of each 
      other.
FAU - Hivnor, Chad M
AU  - Hivnor CM
AD  - Wilford Hall Medical Center, Lackland Air Force Base, Lackland AFB, TX 
      78236-9908, USA. chivnor@pol.net
FAU - Hudkins, Matthew L
AU  - Hudkins ML
FAU - Bonner, Bert
AU  - Bonner B
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Cutis
JT  - Cutis
JID - 0006440
RN  - 0 (Antifungal Agents)
RN  - 0 (Naphthalenes)
RN  - G7RIW8S0XP (Terbinafine)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Antifungal Agents/administration & dosage/*adverse effects
MH  - Dermatomycoses/drug therapy
MH  - Female
MH  - Granuloma/drug therapy
MH  - Humans
MH  - Lupus Erythematosus, Cutaneous/*chemically induced
MH  - Middle Aged
MH  - Naphthalenes/administration & dosage/*adverse effects
MH  - Skin Diseases/drug therapy
MH  - Terbinafine
EDAT- 2008/04/30 09:00
MHDA- 2008/07/04 09:00
CRDT- 2008/04/30 09:00
PHST- 2008/04/30 09:00 [pubmed]
PHST- 2008/07/04 09:00 [medline]
PHST- 2008/04/30 09:00 [entrez]
PST - ppublish
SO  - Cutis. 2008 Feb;81(2):156-7.